Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBIT (2016 - 2025)

Vanda Pharmaceuticals' EBIT history spans 16 years, with the latest figure at -$40.4 million for Q4 2025.

  • For Q4 2025, EBIT fell 292.58% year-over-year to -$40.4 million; the TTM value through Dec 2025 reached -$151.2 million, down 271.79%, while the annual FY2025 figure was -$151.2 million, 271.79% down from the prior year.
  • EBIT for Q4 2025 was -$40.4 million at Vanda Pharmaceuticals, down from -$31.3 million in the prior quarter.
  • Across five years, EBIT topped out at $12.4 million in Q2 2021 and bottomed at -$41.0 million in Q1 2025.
  • The 5-year median for EBIT is -$6.5 million (2023), against an average of -$7.9 million.
  • The largest annual shift saw EBIT surged 8372.8% in 2021 before it plummeted 560.83% in 2024.
  • A 5-year view of EBIT shows it stood at $8.6 million in 2021, then fell by 23.24% to $6.6 million in 2022, then plummeted by 207.01% to -$7.1 million in 2023, then crashed by 44.9% to -$10.3 million in 2024, then crashed by 292.58% to -$40.4 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's EBIT are -$40.4 million (Q4 2025), -$31.3 million (Q3 2025), and -$38.5 million (Q2 2025).